• B Dubois, S Bombois, N Villain, M Teichmann, S Epelbaum, R Migliaccio, R Genthon, B Verrat, C Lesoil, M Levy, I Le Ber, and R Levy.
• Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.
• B Acad Nat Med Paris. 2020 Jun 1; 204 (6): 583-588.

AbstractDementias, and Alzheimer's disease (AD) in particular, will increasingly become a public health issue. However, three major data may change the severity of these pathologies: in young adults, simple measures of healthy lifestyle (control of vascular risk factors, physical activity and cognitive stimulation), have an impact on a future cognitive decline; the same lifestyle interventions may delay the start of the disease for elderly people potentially at-risk; finally, and for the first time, a monoclonal antibody directed against amyloid lesions has just shown a significant effect on the progression of AD in patients at an early stage of the disease. According to these results, we will have to reconsider the strategy for managing minor or severe cognitive disorders and particularly AD. Nowadays, patients start the care process too late. The solution is to act earlier, even preventively. It is necessary to improve a care offer adapted to this new situation in order to impact on the disease as soon as possible, even before the onset of symptoms, based on: 1) predictive algorithms aimed at establishing whose cognitively unimpaired individuals may further develop the disease; these algorithms will be based on demographic, family, cognitive, genomic and biological data, such as in the "Santé Cerveau" project developed in partnership with the Health Regional Agency (ARS) and the general practitioners; 2)and on some expert centers which must become "dementia prevention clinics" to test prevention measures, initiate and validate multi-domain therapeutic education programs; to disclose about the risk in response to the request of worried patients; and to propose early pharmacological treatments if these individuals are on the way to declare AD in the coming months, taking into account competition between risks. This will allow to prepare to make use of new pharmacological treatments that might be discovered.© 2020 Published by Elsevier Masson SAS on behalf of l'Académie nationale de médecine.

4 keywords...

hide…